• 169 Citations
  • 6 h-Index
20082020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Ariella Hanker is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 169 Citations
  • 6 h-Index
  • 6 Article
  • 3 Chapter
  • 3 Comment/debate
  • 2 Review article

Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Brewer, M. R., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & 2 others, Hanker, A. B. & Arteaga, C. L., Feb 10 2020, In : Cancer Cell. 37, 2, p. 258-259 2 p.

Research output: Contribution to journalComment/debate

Open Access
  • Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

    Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Red Brewer, M., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & 2 others, Hanker, A. B. & Arteaga, C. L., Feb 10 2020, In : Cancer Cell. 37, 2, p. 183-199.e5

    Research output: Contribution to journalArticle

  • Overcoming Endocrine Resistance in Breast Cancer

    Hanker, A. B., Sudhan, D. R. & Arteaga, C. L., Apr 13 2020, In : Cancer Cell. 37, 4, p. 496-513 18 p.

    Research output: Contribution to journalReview article

  • 1 Scopus citations

    Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

    Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, O’Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M. & Arteaga, C. L., Dec 1 2019, In : Nature communications. 10, 1, 1373.

    Research output: Contribution to journalArticle

    Open Access
  • 28 Scopus citations

    Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors

    Hanker, A. B., Kaklamani, V. & Arteaga, C. L., Apr 2019, In : Cancer discovery. 9, 4, p. 482-491 10 p.

    Research output: Contribution to journalArticle

  • 20 Scopus citations